|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||7.66 - 8.05|
|52 Week Range||0.39 - 18.10|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.67|
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association ...
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
-- Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne Muscular Dystrophy --
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York City, NY.
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathizeRead More...
The Company Will Host a Conference Call at 8:30am ET
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today shared additional clinical results from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, boys with Duchenne muscular dystrophy (DMD) treated with edasalonexent on average grew in line with the growth of unaffected boys in the same age range.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Global Pharmaceutical Development and Operations at Celgene. “Joanne brings deep knowledge of pharmaceutical development and operations to Catabasis, and we are excited to have her join our board of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors.
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at a public offering price of $5.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering.
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jill Milne has been the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) since 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Catabasis Pharmaceuticals, Inc. (CATB) has been struggling lately, but the selling pressure may be coming to an end soon.